Title : Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.

Pub. Date : 2020 Jun

PMID : 32436611






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Interestingly, in the taxane combination group, patients with TP53 mutations exhibited longer PFS than those without TP53 mutations (hazard ratio = 0.08, 95% CI = 0.02-0.30, P < 0.001). taxane tumor protein p53 Homo sapiens
2 Interestingly, in the taxane combination group, patients with TP53 mutations exhibited longer PFS than those without TP53 mutations (hazard ratio = 0.08, 95% CI = 0.02-0.30, P < 0.001). taxane tumor protein p53 Homo sapiens
3 However, in the non-taxane combination group, patients with TP53 mutations displayed shorter PFS than those with wild-type TP53 (hazard ratio = 4.84, 95% CI = 1.60-14.66, P = 0.005). taxane tumor protein p53 Homo sapiens
4 However, in the non-taxane combination group, patients with TP53 mutations displayed shorter PFS than those with wild-type TP53 (hazard ratio = 4.84, 95% CI = 1.60-14.66, P = 0.005). taxane tumor protein p53 Homo sapiens